000153412012/312025Q3FALSEhttp://fasb.org/us-gaap/2025#DerivativeLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2025#DerivativeLiabilitiesNoncurrenthttp://www.avalotherapeutics.com/20250930#PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortizationhttp://www.avalotherapeutics.com/20250930#PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortizationhttp://fasb.org/us-gaap/2025#AccruedLiabilitiesAndOtherLiabilitieshttp://fasb.org/us-gaap/2025#AccruedLiabilitiesAndOtherLiabilitieshttp://fasb.org/us-gaap/2025#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2025#OtherLiabilitiesNoncurrentP1YP6Mxbrli:sharesiso4217:USDiso4217:USDxbrli:sharesxbrli:pureavtx:class_of_stockavtx:employeeavtx:segment00015341202025-01-012025-09-3000015341202025-11-0300015341202025-09-3000015341202024-12-310001534120us-gaap:SeriesDPreferredStockMember2024-12-310001534120us-gaap:SeriesDPreferredStockMember2025-09-300001534120us-gaap:SeriesEPreferredStockMember2024-12-310001534120us-gaap:SeriesEPreferredStockMember2025-09-300001534120us-gaap:SeriesCPreferredStockMember2025-09-300001534120us-gaap:SeriesCPreferredStockMember2024-12-310001534120us-gaap:ProductMember2025-07-012025-09-300001534120us-gaap:ProductMember2024-07-012024-09-300001534120us-gaap:ProductMember2025-01-012025-09-300001534120us-gaap:ProductMember2024-01-012024-09-3000015341202025-07-012025-09-3000015341202024-07-012024-09-3000015341202024-01-012024-09-3000015341202025-06-300001534120us-gaap:CommonStockMember2025-06-300001534120us-gaap:SeriesCPreferredStockMemberus-gaap:PreferredStockMember2025-06-300001534120us-gaap:AdditionalPaidInCapitalMember2025-06-300001534120us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-06-300001534120us-gaap:RetainedEarningsMember2025-06-300001534120us-gaap:CommonStockMember2025-07-012025-09-300001534120us-gaap:SeriesCPreferredStockMemberus-gaap:PreferredStockMember2025-07-012025-09-300001534120us-gaap:AdditionalPaidInCapitalMember2025-07-012025-09-300001534120us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-07-012025-09-300001534120us-gaap:RetainedEarningsMember2025-07-012025-09-300001534120us-gaap:CommonStockMember2025-09-300001534120us-gaap:SeriesCPreferredStockMemberus-gaap:PreferredStockMember2025-09-300001534120us-gaap:AdditionalPaidInCapitalMember2025-09-300001534120us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-09-300001534120us-gaap:RetainedEarningsMember2025-09-300001534120us-gaap:CommonStockMember2024-12-310001534120us-gaap:SeriesCPreferredStockMemberus-gaap:PreferredStockMember2024-12-310001534120us-gaap:AdditionalPaidInCapitalMember2024-12-310001534120us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-12-310001534120us-gaap:RetainedEarningsMember2024-12-310001534120us-gaap:CommonStockMember2025-01-012025-09-300001534120us-gaap:SeriesCPreferredStockMemberus-gaap:PreferredStockMember2025-01-012025-09-300001534120us-gaap:AdditionalPaidInCapitalMember2025-01-012025-09-300001534120us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-01-012025-09-300001534120us-gaap:RetainedEarningsMember2025-01-012025-09-3000015341202024-06-300001534120us-gaap:CommonStockMember2024-06-300001534120us-gaap:SeriesCPreferredStockMemberus-gaap:PreferredStockMember2024-06-300001534120us-gaap:AdditionalPaidInCapitalMember2024-06-300001534120us-gaap:RetainedEarningsMember2024-06-300001534120avtx:ConversionOfConvertiblePreferredStockMemberus-gaap:CommonStockMember2024-07-012024-09-300001534120avtx:ConversionOfConvertiblePreferredStockMemberus-gaap:AdditionalPaidInCapitalMember2024-07-012024-09-300001534120avtx:ConversionOfConvertiblePreferredStockMember2024-07-012024-09-300001534120us-gaap:AdditionalPaidInCapitalMember2024-07-012024-09-300001534120us-gaap:RetainedEarningsMember2024-07-012024-09-3000015341202024-09-300001534120us-gaap:CommonStockMember2024-09-300001534120us-gaap:SeriesCPreferredStockMemberus-gaap:PreferredStockMember2024-09-300001534120us-gaap:AdditionalPaidInCapitalMember2024-09-300001534120us-gaap:RetainedEarningsMember2024-09-3000015341202023-12-310001534120us-gaap:CommonStockMember2023-12-310001534120us-gaap:SeriesCPreferredStockMemberus-gaap:PreferredStockMember2023-12-310001534120us-gaap:AdditionalPaidInCapitalMember2023-12-310001534120us-gaap:RetainedEarningsMember2023-12-310001534120us-gaap:CommonStockMember2024-01-012024-09-300001534120us-gaap:AdditionalPaidInCapitalMember2024-01-012024-09-300001534120avtx:AlmataBioTransactionMemberus-gaap:SeriesCPreferredStockMember2024-01-012024-09-300001534120us-gaap:SeriesCPreferredStockMemberus-gaap:PrivatePlacementMember2024-01-012024-09-300001534120us-gaap:SeriesDPreferredStockMemberus-gaap:PrivatePlacementMember2024-01-012024-09-300001534120us-gaap:SeriesEPreferredStockMemberus-gaap:PrivatePlacementMember2024-01-012024-09-300001534120avtx:ConversionOfConvertiblePreferredStockMemberus-gaap:CommonStockMember2024-01-012024-09-300001534120avtx:ConversionOfConvertiblePreferredStockMemberus-gaap:AdditionalPaidInCapitalMember2024-01-012024-09-300001534120avtx:ConversionOfConvertiblePreferredStockMember2024-01-012024-09-300001534120us-gaap:RetainedEarningsMember2024-01-012024-09-300001534120srt:RevisionOfPriorPeriodReclassificationAdjustmentMember2024-12-310001534120srt:RevisionOfPriorPeriodReclassificationAdjustmentMember2024-09-300001534120avtx:AlmataBioTransactionMember2024-03-272024-03-270001534120us-gaap:SeriesCPreferredStockMemberavtx:AlmataTransactionAndMarch2024FinancingMember2024-03-272024-03-270001534120us-gaap:SeriesCPreferredStockMemberavtx:AlmataTransactionAndMarch2024FinancingMember2024-08-132024-08-130001534120avtx:AlmataBioTransactionMemberus-gaap:CommonStockMember2024-08-132024-08-130001534120avtx:AlmataBioTransactionMember2024-03-282024-03-280001534120avtx:AlmataBioTransactionMember2024-04-012024-04-300001534120avtx:MilestoneOneMemberavtx:AlmataBioTransactionMember2024-03-280001534120avtx:MilestoneTwoMemberavtx:AlmataBioTransactionMember2024-03-280001534120avtx:MilestoneOneMemberavtx:AlmataBioTransactionMember2024-10-012024-10-310001534120avtx:AlmataBioTransactionMember2024-01-012024-09-300001534120avtx:AlmataBioTransactionMember2024-09-300001534120avtx:AlmataBioTransactionMember2024-08-132024-08-130001534120avtx:AlmataBioTransactionMember2024-03-270001534120avtx:MillipredMember2021-07-012023-09-300001534120us-gaap:EmployeeStockOptionMember2025-07-012025-09-300001534120us-gaap:EmployeeStockOptionMember2025-01-012025-09-300001534120us-gaap:EmployeeStockOptionMember2024-07-012024-09-300001534120us-gaap:EmployeeStockOptionMember2024-01-012024-09-300001534120avtx:WarrantCommonStockMember2025-07-012025-09-300001534120avtx:WarrantCommonStockMember2025-01-012025-09-300001534120avtx:WarrantCommonStockMember2024-07-012024-09-300001534120avtx:WarrantCommonStockMember2024-01-012024-09-300001534120us-gaap:SeriesCPreferredStockMember2025-07-012025-09-300001534120us-gaap:SeriesCPreferredStockMember2025-01-012025-09-300001534120us-gaap:SeriesCPreferredStockMember2024-01-012024-09-300001534120us-gaap:SeriesCPreferredStockMember2024-07-012024-09-300001534120us-gaap:RestrictedStockUnitsRSUMember2025-07-012025-09-300001534120us-gaap:RestrictedStockUnitsRSUMember2025-01-012025-09-300001534120us-gaap:RestrictedStockUnitsRSUMember2024-07-012024-09-300001534120us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-09-300001534120us-gaap:PerformanceSharesMember2025-01-012025-09-300001534120us-gaap:PerformanceSharesMember2025-07-012025-09-300001534120us-gaap:PerformanceSharesMember2024-07-012024-09-300001534120us-gaap:PerformanceSharesMember2024-01-012024-09-300001534120us-gaap:SeriesCPreferredStockMember2024-09-300001534120us-gaap:SeriesCPreferredStockMember2025-09-300001534120us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2025-09-300001534120us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2025-09-300001534120us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2025-09-300001534120us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2025-09-300001534120us-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2025-09-300001534120us-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2025-09-300001534120us-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2025-09-300001534120us-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueMeasurementsRecurringMember2025-09-300001534120us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2025-09-300001534120us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2025-09-300001534120us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2025-09-300001534120us-gaap:FairValueMeasurementsRecurringMember2025-09-300001534120us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2024-12-310001534120us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2024-12-310001534120us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2024-12-310001534120us-gaap:FairValueMeasurementsRecurringMember2024-12-310001534120us-gaap:DerivativeFinancialInstrumentsLiabilitiesMemberus-gaap:FairValueInputsLevel3Member2025-06-300001534120us-gaap:FairValueInputsLevel3Member2025-06-300001534120us-gaap:DerivativeFinancialInstrumentsLiabilitiesMemberus-gaap:FairValueInputsLevel3Member2025-07-012025-09-300001534120us-gaap:FairValueInputsLevel3Member2025-07-012025-09-300001534120us-gaap:DerivativeFinancialInstrumentsLiabilitiesMemberus-gaap:FairValueInputsLevel3Member2025-09-300001534120us-gaap:FairValueInputsLevel3Member2025-09-300001534120us-gaap:DerivativeFinancialInstrumentsLiabilitiesMemberus-gaap:FairValueInputsLevel3Member2024-12-310001534120us-gaap:FairValueInputsLevel3Member2024-12-310001534120us-gaap:DerivativeFinancialInstrumentsLiabilitiesMemberus-gaap:FairValueInputsLevel3Member2025-01-012025-09-300001534120us-gaap:FairValueInputsLevel3Member2025-01-012025-09-300001534120us-gaap:WarrantMemberus-gaap:FairValueInputsLevel3Member2024-06-300001534120us-gaap:DerivativeFinancialInstrumentsLiabilitiesMemberus-gaap:FairValueInputsLevel3Member2024-06-300001534120us-gaap:FairValueInputsLevel3Member2024-06-300001534120us-gaap:WarrantMemberus-gaap:FairValueInputsLevel3Member2024-07-012024-09-300001534120us-gaap:DerivativeFinancialInstrumentsLiabilitiesMemberus-gaap:FairValueInputsLevel3Member2024-07-012024-09-300001534120us-gaap:FairValueInputsLevel3Member2024-07-012024-09-300001534120us-gaap:WarrantMemberus-gaap:FairValueInputsLevel3Member2024-09-300001534120us-gaap:DerivativeFinancialInstrumentsLiabilitiesMemberus-gaap:FairValueInputsLevel3Member2024-09-300001534120us-gaap:FairValueInputsLevel3Member2024-09-300001534120us-gaap:WarrantMemberus-gaap:FairValueInputsLevel3Member2023-12-310001534120us-gaap:DerivativeFinancialInstrumentsLiabilitiesMemberus-gaap:FairValueInputsLevel3Member2023-12-310001534120us-gaap:FairValueInputsLevel3Member2023-12-310001534120us-gaap:WarrantMemberus-gaap:FairValueInputsLevel3Member2024-01-012024-09-300001534120us-gaap:DerivativeFinancialInstrumentsLiabilitiesMemberus-gaap:FairValueInputsLevel3Member2024-01-012024-09-300001534120us-gaap:FairValueInputsLevel3Member2024-01-012024-09-300001534120avtx:ESTherapeuticsMemberus-gaap:DerivativeFinancialInstrumentsLiabilitiesMember2022-10-012022-12-310001534120avtx:AVTX501Member2022-12-310001534120avtx:AVTX007Memberavtx:MilestoneOneMember2022-12-310001534120avtx:AVTX007Memberavtx:MilestoneTwoMember2022-12-310001534120avtx:AVTX611Member2022-12-310001534120avtx:AVTX501AndAVTX007Memberus-gaap:DerivativeFinancialInstrumentsLiabilitiesMember2022-10-012022-12-310001534120avtx:AVTX501Memberus-gaap:DerivativeFinancialInstrumentsLiabilitiesMember2022-10-012022-12-310001534120avtx:AVTX007Memberus-gaap:DerivativeFinancialInstrumentsLiabilitiesMember2022-10-012022-12-310001534120avtx:AVTX007Memberus-gaap:DerivativeFinancialInstrumentsLiabilitiesMember2025-09-300001534120avtx:AVTX501AndAVTX007Memberus-gaap:DerivativeFinancialInstrumentsLiabilitiesMember2025-07-012025-09-300001534120avtx:AVTX501AndAVTX007Memberus-gaap:DerivativeFinancialInstrumentsLiabilitiesMember2025-01-012025-09-300001534120avtx:AVTX501Memberus-gaap:DerivativeFinancialInstrumentsLiabilitiesMemberavtx:MeasurementInputProbabilityOfSuccessMember2022-12-310001534120avtx:AVTX007Memberus-gaap:DerivativeFinancialInstrumentsLiabilitiesMemberavtx:MeasurementInputSalesForecastPeakMember2022-10-012022-12-310001534120avtx:AVTX007Memberus-gaap:DerivativeFinancialInstrumentsLiabilitiesMemberavtx:MeasurementInputProbabilityOfSuccessMember2022-12-310001534120avtx:AVTX007Memberus-gaap:DerivativeFinancialInstrumentsLiabilitiesMemberus-gaap:MeasurementInputExpectedTermMember2022-10-012022-12-310001534120us-gaap:PrivatePlacementMemberus-gaap:WarrantMember2025-09-300001534120us-gaap:PrivatePlacementMemberus-gaap:WarrantMember2024-12-310001534120us-gaap:WarrantMemberus-gaap:FairValueInputsLevel3Member2024-03-282024-03-280001534120us-gaap:PrivatePlacementMemberus-gaap:PreferredStockMember2022-10-012022-12-3100015341202022-10-012022-12-310001534120us-gaap:MoneyMarketFundsMember2025-09-300001534120us-gaap:USTreasuryAndGovernmentMember2025-09-300001534120us-gaap:CashAndCashEquivalentsMember2025-09-300001534120us-gaap:CashAndCashEquivalentsMember2024-12-310001534120us-gaap:ShortTermInvestmentsMember2025-09-300001534120us-gaap:ShortTermInvestmentsMember2024-12-310001534120stpr:PAus-gaap:BuildingMember2025-09-300001534120stpr:PAus-gaap:BuildingMember2025-01-012025-09-300001534120stpr:MDus-gaap:BuildingMember2024-10-012024-12-310001534120stpr:MDus-gaap:BuildingMember2025-01-012025-09-300001534120stpr:MDus-gaap:BuildingMember2025-09-300001534120us-gaap:SeriesCPreferredStockMemberus-gaap:PrivatePlacementMember2024-03-282024-03-280001534120us-gaap:PrivatePlacementMemberus-gaap:WarrantMember2024-03-282024-03-280001534120us-gaap:PrivatePlacementMemberus-gaap:PreferredStockMember2024-03-282024-03-280001534120us-gaap:PrivatePlacementMember2024-03-282024-03-280001534120us-gaap:PrivatePlacementMember2024-10-012024-12-310001534120us-gaap:SeriesCPreferredStockMemberus-gaap:PrivatePlacementMember2024-08-132024-08-130001534120us-gaap:CommonStockMember2024-08-132024-08-130001534120us-gaap:CommonStockMember2024-10-012024-12-310001534120us-gaap:SeriesCPreferredStockMember2024-10-012024-12-310001534120us-gaap:FairValueInputsLevel3Memberus-gaap:WarrantMember2025-09-300001534120us-gaap:WarrantMemberus-gaap:FairValueInputsLevel3Member2024-10-012024-12-310001534120us-gaap:PrivatePlacementMemberus-gaap:AdditionalPaidInCapitalMember2024-10-012024-12-310001534120avtx:AlmataTransactionAndMarch2024FinancingMember2025-09-300001534120us-gaap:SeriesCPreferredStockMemberavtx:AlmataTransactionAndMarch2024FinancingMember2025-09-300001534120avtx:AlmataTransactionAndMarch2024FinancingMember2024-10-012024-12-310001534120us-gaap:SeriesCPreferredStockMemberavtx:AlmataTransactionAndMarch2024FinancingMember2024-12-310001534120us-gaap:SeriesCPreferredStockMemberavtx:AlmataBioTransactionAndMarch2024FinancingMemberus-gaap:AdditionalPaidInCapitalMember2024-12-310001534120us-gaap:SeriesCPreferredStockMember2025-07-012025-09-300001534120us-gaap:SeriesCPreferredStockMember2025-01-012025-09-300001534120avtx:ATMAgreementMember2025-06-012025-06-300001534120avtx:ATMAgreementMember2025-01-012025-09-300001534120avtx:ATMAgreementMember2025-07-012025-09-300001534120avtx:CommonStockWarrantsExpirationJune2031Memberus-gaap:CommonClassAMember2025-09-300001534120avtx:A2016ThirdAmendedPlanMember2025-01-012025-09-300001534120avtx:A2016FourthAmendedPlanMember2025-01-012025-01-010001534120avtx:A2016ThirdAmendedPlanMember2025-09-300001534120avtx:InducementAwardPlanMember2025-09-300001534120avtx:InducementAwardPlanMember2025-01-012025-09-300001534120avtx:A2016ThirdAmendedPlanMemberus-gaap:EmployeeStockOptionMember2025-01-012025-09-300001534120us-gaap:EmployeeStockOptionMembersrt:MaximumMemberavtx:A2016ThirdAmendedPlanMemberus-gaap:ShareBasedPaymentArrangementEmployeeMember2025-01-012025-09-300001534120us-gaap:EmployeeStockOptionMembersrt:MinimumMemberavtx:A2016ThirdAmendedPlanMembersrt:DirectorMember2025-01-012025-09-300001534120us-gaap:EmployeeStockOptionMembersrt:MaximumMemberavtx:A2016ThirdAmendedPlanMembersrt:DirectorMember2025-01-012025-09-300001534120us-gaap:ResearchAndDevelopmentExpenseMember2025-07-012025-09-300001534120us-gaap:ResearchAndDevelopmentExpenseMember2024-07-012024-09-300001534120us-gaap:ResearchAndDevelopmentExpenseMember2025-01-012025-09-300001534120us-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-09-300001534120us-gaap:GeneralAndAdministrativeExpenseMember2025-07-012025-09-300001534120us-gaap:GeneralAndAdministrativeExpenseMember2024-07-012024-09-300001534120us-gaap:GeneralAndAdministrativeExpenseMember2025-01-012025-09-300001534120us-gaap:GeneralAndAdministrativeExpenseMember2024-01-012024-09-300001534120avtx:ServiceBasedOptionsMember2024-12-310001534120avtx:ServiceBasedOptionsMember2024-01-012024-12-310001534120avtx:ServiceBasedOptionsMember2025-01-012025-09-300001534120avtx:ServiceBasedOptionsMember2025-09-300001534120avtx:ServiceBasedOptionsMember2024-01-012024-09-300001534120avtx:ServiceBasedOptionsMember2025-07-012025-09-300001534120avtx:ServiceBasedOptionsMember2024-07-012024-09-300001534120srt:MinimumMemberavtx:ServiceBasedOptionsMember2025-09-300001534120srt:MaximumMemberavtx:ServiceBasedOptionsMember2025-09-300001534120srt:MinimumMemberavtx:ServiceBasedOptionsMember2025-01-012025-09-300001534120srt:MaximumMemberavtx:ServiceBasedOptionsMember2025-01-012025-09-300001534120us-gaap:RestrictedStockUnitsRSUMember2024-12-310001534120us-gaap:RestrictedStockUnitsRSUMember2025-01-012025-09-300001534120us-gaap:RestrictedStockUnitsRSUMember2025-09-300001534120us-gaap:RestrictedStockUnitsRSUMember2024-08-132024-08-130001534120us-gaap:RestrictedStockUnitsRSUMember2025-07-012025-09-300001534120us-gaap:RestrictedStockUnitsRSUMember2024-07-012024-09-300001534120us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-09-300001534120avtx:A2016FourthAmendedPlanMemberus-gaap:PerformanceSharesMember2025-08-012025-08-310001534120avtx:A2016FourthAmendedPlanMemberus-gaap:PerformanceSharesMember2025-01-012025-09-300001534120us-gaap:PerformanceSharesMember2025-09-300001534120us-gaap:PerformanceSharesMembersrt:MaximumMemberavtx:A2016FourthAmendedPlanMember2025-01-012025-09-300001534120srt:MinimumMemberus-gaap:PerformanceSharesMember2025-09-300001534120srt:MaximumMemberus-gaap:PerformanceSharesMember2025-09-300001534120us-gaap:EmployeeStockMember2016-04-052016-04-050001534120us-gaap:EmployeeStockMember2016-04-050001534120us-gaap:EmployeeStockMember2025-01-012025-01-010001534120us-gaap:EmployeeStockMember2025-01-012025-09-300001534120us-gaap:EmployeeStockMember2025-07-012025-09-300001534120avtx:LillyLicenseAgreementMemberavtx:AVTX009LillyLicenseAgreementMember2024-03-270001534120avtx:AVTX009LillyLicenseAgreementMemberavtx:LillyLicenseAgreementMembersrt:MinimumMember2024-03-270001534120avtx:AVTX009LillyLicenseAgreementMemberavtx:LillyLicenseAgreementMembersrt:MaximumMember2024-03-270001534120avtx:LillyLicenseAgreementMemberavtx:AVTX009LillyLicenseAgreementMember2024-03-272024-03-270001534120avtx:LillyLicenseAgreementMemberavtx:AVTX009LillyLicenseAgreementMember2025-01-012025-09-300001534120avtx:LillyLicenseAgreementMemberavtx:AVTX009LillyLicenseAgreementMember2025-07-012025-09-300001534120avtx:LillyLicenseAgreementMemberavtx:AVTX009LillyLicenseAgreementMember2025-09-300001534120avtx:KyowaKirinCoLtdKKCMemberavtx:AVTX002KKCLicenseAgreementMember2021-03-250001534120avtx:MilestoneOneMemberavtx:AVTX002KKCLicenseAgreementMemberavtx:KyowaKirinCoLtdKKCMember2021-03-250001534120avtx:MilestoneTwoMemberavtx:AVTX002KKCLicenseAgreementMemberavtx:KyowaKirinCoLtdKKCMember2021-03-250001534120avtx:KyowaKirinCoLtdKKCMemberus-gaap:ContractTerminationMembersrt:MinimumMember2021-03-252021-03-250001534120avtx:KyowaKirinCoLtdKKCMemberus-gaap:ContractTerminationMembersrt:MaximumMember2021-03-252021-03-250001534120avtx:KyowaKirinCoLtdKKCMemberavtx:AVTX002KKCLicenseAgreementMember2025-07-012025-09-300001534120avtx:KyowaKirinCoLtdKKCMemberavtx:AVTX002KKCLicenseAgreementMember2025-01-012025-09-300001534120avtx:KyowaKirinCoLtdKKCMemberavtx:AVTX002KKCLicenseAgreementMember2025-09-300001534120avtx:CHOPLicenseAgreementMemberavtx:AVTX002KKCLicenseAgreementMember2020-02-030001534120avtx:CHOPLicenseAgreementMemberavtx:AVTX002KKCLicenseAgreementMember2020-02-032020-02-030001534120avtx:CHOPLicenseAgreementMemberavtx:AVTX002KKCLicenseAgreementMember2025-09-300001534120avtx:CHOPLicenseAgreementMember2020-02-032020-02-030001534120avtx:CHOPLicenseAgreementMemberus-gaap:ContractTerminationMember2020-02-032020-02-030001534120avtx:AstellasPharmaIncAstellasMemberavtx:AVTX006AstellasLicenseAgreementMember2019-07-150001534120avtx:AstellasPharmaIncAstellasMemberavtx:AVTX006Member2019-07-152019-07-150001534120avtx:AstellasPharmaIncAstellasMember2019-07-152019-07-150001534120avtx:AstellasPharmaIncAstellasMemberavtx:AVTX006AstellasLicenseAgreementMember2025-01-012025-09-300001534120avtx:AstellasPharmaIncAstellasMemberavtx:AVTX006AstellasLicenseAgreementMember2025-07-012025-09-300001534120avtx:AstellasPharmaIncAstellasMemberavtx:AVTX006AstellasLicenseAgreementMember2025-09-300001534120avtx:AltoMemberavtx:AVTX301OutLicenseMember2021-05-280001534120avtx:AVTX301OutLicenseMember2021-05-282021-05-280001534120avtx:AltoMemberavtx:AVTX301OutLicenseMember2025-09-300001534120avtx:AVTX406LicenseAssignmentMemberavtx:MilestoneOneMemberavtx:ESMember2021-06-090001534120avtx:AVTX406LicenseAssignmentMemberavtx:MilestoneTwoMemberavtx:ESMember2021-06-090001534120avtx:ESMemberavtx:AVTX406LicenseAssignmentMember2025-09-300001534120avtx:AVTX800SeriesAssetSaleMemberavtx:PurchaseAgreementMemberavtx:AUGTherapeuticsLLCMember2023-10-272023-10-270001534120avtx:AVTX800SeriesAssetSaleMemberavtx:PurchaseAgreementMemberavtx:AUGTherapeuticsLLCMember2023-10-270001534120avtx:AVTX009Memberavtx:MilestoneTwoMember2024-04-300001534120avtx:AVTX009Memberavtx:MilestoneThreeMember2024-10-012024-10-3100015341202019-07-012019-07-310001534120avtx:ReportableSegmentMember2025-07-012025-09-300001534120avtx:ReportableSegmentMember2024-07-012024-09-300001534120avtx:ReportableSegmentMember2025-01-012025-09-300001534120avtx:ReportableSegmentMember2024-01-012024-09-30

(Exact name of registrant as specified in its charter)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading Symbol			Name of each exchange on which registered
Common Stock, $0.001 par value			AVTX			Nasdaq Capital Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☑ No ☐ 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☑ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b‑2 of the Exchange Act.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b‑2 of the Exchange Act). Yes ☐  No ☑

As of November 3, 2025, the registrant had 18,133,968 shares of common stock outstanding.

 

 

 

 

 

						Three Months Ended												Nine Months Ended
						September 30,												September 30,
						2025						2024						2025						2024
Revenues:
Product revenue, net						$	—					$	249					$	—					$	249
Total revenues, net						—						249						—						249
Operating expenses:
Cost of product sales						$	—					$	(714)					$	—					$	(453)
Research and development						13,621						9,538						36,817						16,254
General and administrative						5,577						4,286						16,366						12,008
Acquired in-process research and development						—						—						—						27,641
Total operating expenses						19,198						13,110						53,183						55,450
Loss from operations						(19,198)						(12,861)						(53,183)						(55,201)
Other (expense) income:
Change in fair value of derivative liability						(12,530)						(1,100)						(14,680)						(6,260)
Interest income, net						1,117						964						3,367						2,101
Excess of initial warrant fair value over private placement proceeds						—						—						—						(79,276)
Change in fair value of warrant liability						—						36,025						—						148,071
Private placement transaction costs						—						—						—						(9,220)
Other expense, net						(3)						(5)						(8)						(5)
Total other (expense) income, net						(11,416)						35,884						(11,321)						55,411
(Loss) income before taxes						(30,614)						23,023						(64,504)						210
Income tax expense (benefit)						11						(14)						35						—
Net (loss) income						$	(30,625)					$	23,037					$	(64,539)					$	210
Net (loss) income per share of common stock - basic						$	(2.19)					$	0.98					$	(5.47)					$	0.01
Net loss per share of common stock - diluted						$	(2.19)					$	(2.83)					$	(5.47)					$	(22.63)
Weighted average common shares outstanding - basic						14,000,451						5,546,257						11,795,810						2,491,114
Weighted average common shares outstanding - diluted						14,000,451						10,784,037						11,795,810						6,540,963
Comprehensive (loss) income:
Net (loss) income						$	(30,625)					$	23,037					$	(64,539)					$	210
Other comprehensive loss:
Unrealized income on investments, net						75						—						41						—
Comprehensive (loss) income						$	(30,550)					$	23,037					$	(64,498)					$	210

The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the condensed consolidated balance sheets that sum to the total of the same such amounts shown in the condensed consolidated statements of cash flows (in thousands):

 

Avalo was incorporated in Delaware and commenced operation in 2011, and completed its initial public offering in October 2015.

In accordance with Accounting Standards Codification Topic 205-40, Presentation of Financial Statements - Going Concern, the Company evaluated its ability to continue as a going concern within one year after the date that the accompanying condensed consolidated financial statements are issued. Based on our current operating plans, we expect that our existing cash and cash equivalents and short-term investments are sufficient to fund operations for at least twelve months from the filing date of this Quarterly Report on Form 10-Q. The Company closely monitors its cash and cash equivalents and short-term investments and seeks to balance the level of cash and cash equivalents with our projected needs to allow us to withstand periods of uncertainty relative to the availability of funding on favorable terms. We may satisfy any future cash needs through sales of equity securities under the Company’s at-the-market program or other equity financings, out-licensing transactions, strategic alliances/collaborations, sale of programs, and/or mergers and acquisitions. There can be no assurance that any financing or business development initiatives can be realized by the Company, or if realized, what the terms may be. To the extent that we raise capital through the sale of equity, the ownership interest of our existing stockholders will be diluted, and the terms may include liquidation or other preferences that adversely affect the rights of our stockholders. Further, if the Company raises additional funds through collaborations, strategic alliances or licensing arrangements with third parties, the Company might have to relinquish valuable rights to its technologies, future revenue streams, research programs or product candidates.

 

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Updates (“ASU”) of the Financial Accounting Standards Board (the “FASB”). The unaudited condensed consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets, and the satisfaction of liabilities in the ordinary course of business.

In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments, which are necessary to present fairly the Company’s financial position, results of operations, and cash flows. The condensed consolidated balance sheet at December 31, 2024 has been derived from audited financial statements at that date. The interim results of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain information and footnote disclosure normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to instructions, rules, and regulations prescribed by the United States Securities and Exchange Commission (“SEC”).

The Company believes that the disclosures provided herein are adequate to make the information presented not misleading when these unaudited condensed consolidated financial statements are read in conjunction with the December 31, 2024 audited consolidated financial statements.

In the first quarter of 2025, the Company concluded that it would include other receivables within the prepaid and other current assets line in the Company’s unaudited condensed consolidated balance sheets and statement of cash flows. The Company reclassified $0.6 million from other receivables to prepaid and current assets as of December 31, 2024 within the unaudited condensed consolidated balance sheets and $0.9 million from other receivables to prepaid and other current assets for the nine months ended September 30, 2024 within the unaudited statement of cash flows, to conform with the current period presentation.

Unless otherwise indicated, all amounts in the following tables are in thousands except share and per share amounts.

During the nine months ended September 30, 2025, there were no significant changes to the Company’s summary of significant accounting policies contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, as filed with the SEC on March 20, 2025, except for the policies as described below.

The Company considers all highly liquid investments with an original maturity of three months or fewer when purchased to be cash equivalents. These assets include investments in money market funds and U.S. Treasury securities. Cash equivalents are reflected at fair value, as further described in Note 6 - Fair Value Measurements.

The primary financial instruments that subject the Company to concentrated credit risk include cash, cash equivalents, and short-term investments. The Company maintains its cash, cash equivalents, and short-term investments with high-quality financial institutions and, consequently, the Company believes that such funds are subject to minimal credit risk. The Company’s cash equivalents consist of money market funds, which are invested in U.S. Treasury and government agency obligations, and the Company’s short-term investments consist of U.S. Treasury securities. Credit risk in these securities is reduced as a result of the Company’s investment policy to make high credit quality investments with its cash and cash equivalents. The Company’s investment policy limits investment instruments to investment-grade securities with the objective to preserve capital and to maintain liquidity until the funds can be used in business operations.

The Company generally invests its excess cash in money market funds and marketable debt securities. Such investments are included in either cash and cash equivalents (if the original maturity, from the date of purchase, is 90 days or fewer) or short-term investments (if the original maturity, from the date of purchase, is in excess of 90 days and less than 1 year) on the unaudited condensed consolidated balance sheet, as they represent the investment of funds readily convertible to cash to fund current operations. The Company classifies its investments as either trading, held-to-maturity or available-for-sale based on facts and circumstances present at the time it purchases the securities. As of September 30, 2025, all of our investments were classified as available-for-sale, which are reported at fair value at each balance sheet date, and for which fair value measurement data is obtained from independent pricing services. For securities with unrealized holding gains and losses (the adjustments to fair value), when the Company expects to receive cash flows sufficient to recover the amortized cost basis of a security, such gains and losses are included in “Accumulated other comprehensive income (loss)” as a component of stockholders’ equity. The Company identifies credit losses when it does not expect to receive cash flows sufficient to recover the amortized cost basis of a security. On a quarterly basis, the Company evaluates whether decreases in the fair values of its investments are below their amortized cost, and if so, it marks the investment to market through a charge to our unaudited condensed consolidated statements of operations and comprehensive (loss) income. Realized gains and losses, if any, are included in interest income, net on the unaudited condensed consolidated statements of operations and comprehensive (loss) income. The amortized costs of investments are adjusted for amortization of premiums and accretion of discounts to maturity, which is included in interest income, net on the unaudited condensed consolidated statements of operations and comprehensive (loss) income.

In September 2025, the FASB issued ASU 2025-07, Derivatives and Hedging (Topic 815) and Revenue from Contracts with Customers (Topics 606): Derivatives Scope Refinements and Scope Clarification for Share-based Noncash Consideration from a Customer in a Revenue Contract (“ASU 2025-07”), which, among other items, amends the application of derivative accounting to contracts with features based on the operations or activities of one of the parties to the contract. The amendments are expected to (a) reduce the cost and complexity of evaluating whether contracts with features based on the operations or activities of one of the parties to the contract are derivatives, (b) better portray the economics of those contracts in the financial statements, and (c) reduce diversity in practice resulting from the broad application of the current guidance and changing business environment. The standard is effective for fiscal years beginning after December 15, 2026, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2025-07.

In November 2024, the FASB issued ASU 2024-03, Disaggregation of Income Statement Expenses, which requires disaggregation and disclosure of specified information about certain costs and expenses in the notes to the financial statements. The standard is effective for fiscal years beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2024-03.

In December 2023, the FASB issued ASU 2023-09, Income taxes (Topic 740): Improvements to Income Tax Disclosures, which amends guidance to enhance the transparency and decision usefulness of income tax disclosures. It is effective for fiscal years beginning after December 15, 2024. The Company is required to adopt this standard in its Form 10-K for the year ended December 31, 2025, and does not expect it to have a material impact on its consolidated financial statements and related disclosures.

On March 27, 2024, the Company acquired AVTX-009, an anti-IL-1β mAb, through a merger of AlmataBio, Inc. (“AlmataBio”) with and into its wholly owned subsidiary (the “AlmataBio Transaction”). The Company’s acquisition of AlmataBio was structured as a stock-for-stock transaction whereby all outstanding equity interests in AlmataBio were exchanged in a merger for a combination of the Company’s common stock and shares of the Company’s non-voting convertible preferred stock (the “Series C Preferred Stock”), resulting in the issuance of 171,605 shares of Company common stock and 2,412 shares of Series C Preferred Stock. Upon Company stockholder approval on August 13, 2024 and subject to beneficial ownership limitations, 2,063 shares of Series C Preferred Stock issued to former AlmataBio stockholders automatically converted into 2,062,930 shares of common stock.

In addition to the shares issued, a cash payment of $7.5 million was due to the former AlmataBio stockholders upon the closing of a private placement. The private placement closed on March 28, 2024 and the Company paid the $7.5 million in April 2024. The Company is also required to pay potential development milestone payments to the former AlmataBio stockholders, including $5.0 million due upon the first patient dosed in a Phase 2 trial in patients with HS for AVTX-009, and $15.0 million due upon the first patient dosed in a Phase 3 trial for AVTX-009, both of which are payable in cash or Avalo stock at the election of the former AlmataBio stockholders, subject to the terms and conditions of the definitive merger agreement. In October 2024, the first development milestone was met and the Company paid the $5.0 million cash payment.

The Company was the acquiring company for accounting purposes. In connection with the AlmataBio Transaction, substantially all of the consideration paid is allocable to the fair value of acquired in-process research and development (“IPR&D”), specifically AVTX-009, and as such the acquisition is treated as an asset acquisition. The Company initially recognized AlmataBio’s assets and liabilities by allocating the accumulated cost of the acquisition based on their relative fair values, as estimated by management. The net assets acquired as of the transaction date have been combined with the assets, liabilities, and results of operations of the Company on consummation of the AlmataBio Transaction. In accordance with ASC 730, Research and Development, the portion of the consideration allocated to the acquired IPR&D, specifically AVTX-009, based on its relative fair value, is included as an operating expense as there is no alternative future use.

Below is a summary of the total consideration, assets acquired and the liabilities assumed in connection with the AlmataBio Transaction (in thousands):

1 Equal to the aggregate common stock issued of 171,605 and the aggregate shares of Series C Preferred Stock issued of 2,412 (as-convertible to 2,412,000 shares of common stock), multiplied by the Company’s closing stock price of $4.75 on March 27, 2024. On August 13, 2024 upon Company stockholder approval and subject to beneficial ownership limitations, 2,063 of the 2,412 shares of Series C Preferred Stock were converted into 2,062,930 shares of common stock.

2 Avalo deemed these milestones probable and estimable as of the transaction close date and therefore included them as part of the GAAP purchase price at close. The milestone payment due upon the close of the private placement was paid in April 2024. The milestone payment due upon the first patient dosed in a Phase 2 trial was paid in October 2024.

The Company’s license and supply agreement for Millipred®, an oral prednisolone indicated across a wide variety of inflammatory conditions, expired, as planned, on September 30, 2023. Avalo considered Millipred® a non-core asset. There was no gross revenue recognized from sales of prescription drugs for the three and nine months ended September 30, 2025 or September 30, 2024. Historically, the Company sold Millipred® in the United States primarily through wholesale distributors, who accounted for substantially all of the Company’s net product revenues and trade receivables. The Company continues to monitor estimates for commercial liabilities for Millipred®, such as sales returns. As additional information becomes available, the Company could recognize expense (or a benefit) for differences between actuals or updated estimates to the reserves previously recognized.

Pursuant to the Millipred® license and supply agreement, Avalo was required to pay the supplier fifty percent of the net profit of the Millipred® product following each calendar quarter, with a $0.5 million quarterly minimum payment contingent on Avalo achieving certain net profit thresholds as stipulated in the agreement. The profit share commenced on July 1, 2021 and ended on September 30, 2023. The net profit share is subject to a reconciliation process, where estimated deductions to arrive at net profit will be reconciled to actuals, which might result in Avalo owing additional amounts to the supplier or vice versa, which would be recognized in cost of product sales.

The Company had two classes of stock outstanding during the three and nine months ended September 30, 2025 and September 30, 2024, common stock and preferred stock. The Company computes net (loss) income per share using the two-class method, as the Series C Preferred Stock participates in distributions with the Company’s common stock. The two-class method of computing net (loss) income per share is an earnings allocation formula that determines net loss for common stock and any participating securities according to dividends declared and participation rights in undistributed earnings. As the Company is in a net loss position for the three and nine months ended September 30, 2025, the two-class method of calculating net loss per share results in no allocation of undistributed losses to participating securities. For the three and nine months ended September 30, 2024, the two class method of calculating net income per share resulted in an allocation of a portion of the net income to participating securities because the Company had net income for the period.

Basic net (loss) income per share for common stock is computed by dividing the sum of distributed and undistributed earnings by the weighted average number of shares outstanding for the period.

Diluted net loss per share includes the potential dilutive effect of common stock equivalents as if such securities were converted or exercised during the period, when the effect is dilutive. Common stock equivalents include: (i) outstanding stock options and restricted stock units which are included under the “treasury stock method” when dilutive; (ii) common stock to be issued upon the exercise of outstanding warrants, which are included under the “treasury stock method” when dilutive, and (iii) preferred stock under the if-converted method. Although the impact of these items is generally anti-dilutive during periods of net loss, the Company will determine whether the common stock equivalents should be included in diluted loss per share pursuant to sequencing rules.

The following tables set forth the computation of basic and diluted net (loss) income per share of common stock for the three and nine months ended September 30, 2025 and September 30, 2024 (in thousands, except share and per share amounts): 

The following outstanding securities have been excluded from the computation of diluted weighted shares outstanding for the three and nine months ended September 30, 2025 and 2024, as they could have been anti-dilutive:

1 Each share of the Company’s Series C Preferred Stock is convertible to 1,000 shares of common stock, subject to certain beneficial ownership limitations.

2 Pursuant to the AlmataBio Transaction, the Company is required to pay potential development milestone payments to the former AlmataBio stockholders in cash or Avalo stock at the election of the former AlmataBio stockholders; refer to Notes 3 and 10 for more information. In the event of a settlement in shares, the number of Avalo shares delivered will vary based on the Company’s stock price. These additional shares are not included in the computation of basic and diluted net (loss) income per share for the three and nine months ended September 30, 2025 and 2024 pursuant to the guidance on contingently issuable shares.

3 Calculated assuming 100% achievement of performance metric.

 

ASC 820, Fair Value Measurements and Disclosures (“ASC 820”) defines fair value as the price that would be received to sell an asset, or paid to transfer a liability, in the principal or most advantageous market in an orderly transaction between market participants on the measurement date. The fair value standard also establishes a three‑level hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The valuation hierarchy is based upon the transparency of inputs to the valuation of an asset or liability on the measurement date. The three levels are defined as follows:

•Level 1—inputs to the valuation methodology are quoted prices (unadjusted) for an identical asset or liability in an active market.

•Level 2—inputs to the valuation methodology include quoted prices for a similar asset or liability in an active market or model‑derived valuations in which all significant inputs are observable for substantially the full term of the asset or liability. 

•Level 3—inputs to the valuation methodology are unobservable and significant to the fair value measurement of the asset or liability.

 

The Company measures the fair value of money market funds based on quoted prices in active markets for identical securities. Investments also include U.S. Treasury securities, which are valued either based on recent trades of securities in inactive markets or based on quoted market prices of similar instruments and other significant inputs derived from, or corroborated by, observable market data.

The following table presents, for each of the fair value hierarchy levels required under ASC 820, the Company’s assets and liabilities that are measured at fair value on a recurring basis (in thousands): 

The carrying amounts reported in the accompanying unaudited condensed consolidated financial statements for cash, restricted cash, prepaid and other current assets, accounts payable, and accrued expenses and other current liabilities approximate their respective fair values because of the short-term nature of these accounts.

The table below summarizes changes in the fair value of the Company’s Level 3 valuations for the three and nine months ended September 30, 2025 and September 30, 2024:

In the fourth quarter of 2022, Avalo sold its economic rights to future milestone and royalty payments for previously out-licensed assets AVTX-501, AVTX-007, and AVTX-611 to ES Therapeutics, LLC (“ES”), an affiliate of Armistice Capital LLC (“Armistice”), in exchange for $5.0 million (the “ES Transaction”). At the time of the transaction, Armistice was a significant stockholder of the Company whose chief investment officer, Steven Boyd, and managing director, Keith Maher, served on Avalo’s Board until August 8, 2022. The ES Transaction was approved in accordance with Avalo’s related party transaction policy.

The economic rights sold include (a) rights to a milestone payment of $20.0 million upon the filing and acceptance of an NDA for AVTX-501 pursuant to an agreement with Janssen Pharmaceutics, Inc., now Johnson & Johnson Innovative Medicine (“J&J”) (the “AVTX-501 Milestone”) and (b) rights to any future milestone payments and royalties relating to AVTX-007 under a license agreement with Apollo AP43 Limited (“Apollo”), including up to $6.25 million of development milestones, up to $67.5 million in sales-based milestones, and royalty payments over a ten year period of a low single digit percentage of annual net sales (which percentage increases to another low single digit percentage if annual net sales exceed a specified threshold) (the “AVTX-007 Milestones and Royalties”). In addition, Avalo waived all its rights to AVTX-611 sales-based payments of up to $20.0 million that were payable by ES.

The exchange of the economic rights of the AVTX-501 Milestone and AVTX-007 Milestones and Royalties for cash met the definition of a derivative instrument. The fair value of the derivative liability is determined using a combination of a scenario-based method and an option pricing method (implemented using a Monte Carlo simulation). The significant inputs including probabilities of success, expected timing, and forecasted sales as well as market-based inputs for volatility, risk-adjusted discount rates and allowance for counterparty credit risk are unobservable and based on the best information available to Avalo. Certain information used in the valuation is inherently limited in nature and could differ from J&J’s and Apollo’s internal estimates.

The fair value of the derivative liability as of the transaction date was approximately $4.8 million, of which $3.5 million was attributable to the AVTX-501 Milestone and $1.3 million was attributable to the AVTX-007 Milestones and Royalties. Subsequent to the transaction date, at each reporting period, the derivative liability is remeasured at fair value. As of September 30, 2025, the fair value of the derivative liability was $23.2 million, all of which was attributable to the AVTX-007 Milestone and Royalties and was classified as a non-current liability. For the three and nine months ended September 30, 2025, the $12.5 million and $14.7 million change in fair value was recognized in other expense, net in the accompanying unaudited condensed consolidated statements of operations and comprehensive (loss) income.

The fair value of the AVTX-501 Milestone was deemed to be de minimis, driven by less than 1% probability of success based on Avalo’s interpretation of an announcement from J&J in March 2025, noting the discontinuation of the aticaprant depression program (previously referred to as AVTX-501 by Avalo), which was the only indication publicly disclosed, paired with a lack of commitment to an alternative indication. The fair value of AVTX-007 Milestones and Royalties was primarily driven by sales forecasts with peak annual net sales reaching $2.0 billion in atopic dermatitis, an approximate 41% probability of success, and an estimated time to commercialization of approximately 7.3 years, based on Avalo’s interpretation of Apollo’s September 2025 announcement that the drug met the primary endpoint in its Phase 2a clinical trial in atopic dermatitis. We estimated these unobservable inputs based on limited publicly available information and therefore could differ from J&J’s and Apollo’s respective internal development plans, assessments of probability of success and other inputs of our fair value calculation. Any changes to these inputs may result in significant changes to the fair value measurement. Notably, the peak annual net sales forecast (for the AVTX-007 Milestones and Royalties) and the probability of success (for both the AVTX-501 Milestone and the AVTX-007 Milestone and Royalties) are the largest drivers of the fair value, so changes to either would likely result in significant changes to their respective fair values.

In the event that J&J and/or Apollo are required to make payment(s) to ES Therapeutics pursuant to the underlying agreements, Avalo will recognize revenue under its existing contracts with those customers for that amount when it is no longer probable there would be a significant revenue reversal with any differences between the fair value of the derivative liability related to that payment immediately prior to the revenue recognition and revenue recognized to be recorded as other expense. However, given Avalo is no longer entitled to collect these payments, the potential ultimate settlement of the payments in the future from J&J and/or Apollo to ES Therapeutics (and the future mark-to-market activity each reporting period) will not impact Avalo’s future cash flows.

In March 2024, the Company closed a private placement investment with institutional investors in which the investors received shares of Series C Preferred Stock and warrants to purchase shares of Avalo’s common stock (or a number of shares of Series C Preferred Stock). Refer to Note 10 - Capital Structure and sub-header “March 2024 Financing” for more information.

The Company determined that the warrants did not satisfy the conditions to be accounted for as equity instruments. As the warrants did not meet the equity contract scope exception, the Company classified the warrants as a derivative liability upon issuance.

The Company’s warrant liability was measured at fair value on the issuance date and was measured at fair value each reporting period thereafter until the warrants were fully exercised in the fourth quarter of 2024. As of September 30, 2025 and December 31, 2024, there were no warrants associated with the private placement outstanding and thus no corresponding warrant liability.

For the initial warrant valuation in the first quarter of 2024 and subsequent fair value measurement at each reporting period prior to exercises, the Company utilized the Black-Scholes option pricing model to measure fair value of the warrants, which required assumptions that were subjective and required judgment. As such, the warrant liability was classified as a Level 3 instrument as its value was based on unobservable market inputs. The initial fair value measurement of the warrant liability was $194.9 million and exceeded the initial gross proceeds received from the private placement of $115.6 million, resulting in a $79.3 million loss at issuance of the excess of initial liability fair value. The warrants were fully exercised in the fourth quarter of 2024. Refer to Note 10 - Capital Structure for additional discussion regarding the issuance of the Series C Preferred Stock and common stock pursuant to the warrant exercises.

No changes in valuation techniques occurred during the three and nine months ended September 30, 2025 and 2024. No transfers of assets between Level 1 and Level 2 of the fair value measurement hierarchy occurred during the three and nine months ended September 30, 2025 and 2024.

The following table summarizes our investments classified as available-for-sale as of September 30, 2025 (in thousands):